Video Interview: What a New Study Reveals About Fallopian Tube Recanalization and Selective Salpingography
In a recent video interview, interventional radiologist Lindsay Machan, MD, discussed his longtime work with selective salpingography and fallopian tube recanalization to assist women with infertility issues, and key findings from a new study that he recently presented at the Society of Interventional Radiology (SIR) conference.
Could fallopian tube recanalization be a more viable and cost-effective option than assisted fertility procedures such as in vitro fertilization (IVF)?
Lindsay Machan, MD and colleagues have noted intriguing findings in a new study looking at the use of selective salpingography and subsequent fallopian tube recanalization for women with infertility issues. Dr. Machan, an interventional radiologist and associate professor in the Department of Radiology at the University of British Columbia, recently presented the study findings at the Society of Interventional Radiology (SIR) conference in Boston.
In a video interview, Dr. Machan noted that the use of selective salpingography revealed significant tubal disease in nearly 16 percent of the patients in the study. Over 56 percent of the study patients who had unilateral or bilateral fallopian tube blockages were able to undergo fallopian tube recanalization, a simple, half-hour procedure that can be done on an outpatient basis, according to Dr. Machan, an associate professor in the Department of Radiology at the University of British Columbia.
Dr. Machan added that the use of sedation with repeat hysterosalpingogram revealed normal fallopian tubes for nearly 24 percent of women who were previously diagnosed with blockages in one or both fallopian tubes.
Dr. Machan has studied and performed selective salpingography and fallopian tube recanalization procedures for over three decades. While the procedures are not new, Dr. Machan said he is hopeful that findings from the new study, reportedly the largest study (involving 956 women) to date on these procedures, will increase the awareness and utilization of these procedures for woman with infertility issues.
For additional insights from Dr. Machan, watch the video below:
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
